The business enables the safe and cost-efficient production of biopharmaceuticals -- and that's been a remarkably lucrative niche.
News & Analysis: Repligen
RGEN earnings call for the period ending March 31, 2019.
Favorable earnings helped to send many stocks higher.
Amazon, Goldman Sachs, and Repligen are all great "forever" investments.
Repligen has grown product revenue 220% since 2014, but it trades at 70 times future earnings. What should investors make of that?
RGEN earnings call for the period ending December 31, 2018.
These biotech suppliers have performed extremely well for investors. Here's why each of them is poised for prosperity.
An underrated biotech, a boring industrials play, and an intriguing cloud company: Here's why these growth stocks deserve your attention.
The under-the-radar biotech reported record quarterly revenue during the third quarter.
Ten years is an awfully long time. A.O. Smith, Albemarle, and Repligen will make it worth the wait for patient investors.